Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-18-741 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 3, 2018 Category: Research Source Type: funding
Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this prog...
Source: NIDDK Funding Opportunities - April 3, 2018 Category: Endocrinology Source Type: funding
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 - Clinical Trial Not Allowed)
Funding Opportunity PA-18-678 from the NIH Guide for Grants and Contracts. The purpose of this concept initiative is to promote etiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 23, 2018 Category: Research Source Type: funding
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)
Funding Opportunity PA-18-677 from the NIH Guide for Grants and Contracts. The purpose of this concept initiative is to promote etiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 23, 2018 Category: Research Source Type: funding
Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-035 from the NIH Guide for Grants and Contracts. NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on m...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 11, 2017 Category: Research Source Type: funding
Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)
NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms wi...
Source: NIDDK Funding Opportunities - December 11, 2017 Category: Endocrinology Source Type: funding
Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)
Funding Opportunity RFA-DK-18-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases. DDRCCs are based on the core concept, whereby shared resources aimed at...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 5, 2017 Category: Research Source Type: funding
Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investig...
Source: NIDDK Funding Opportunities - December 5, 2017 Category: Endocrinology Source Type: funding
Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21 Clinical Trial Optional)
Funding Opportunity PA-18-099 from the NIH Guide for Grants and Contracts. This FOA encourages pilot and feasibility clinical and translational research studies of digestive and liver diseases. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 15, 2017 Category: Research Source Type: funding
Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Optional)
Funding Opportunity PA-18-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 15, 2017 Category: Research Source Type: funding
Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this prog...
Source: NIDDK Funding Opportunities - November 15, 2017 Category: Endocrinology Source Type: funding
Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21 Clinical Trial Optional)
This FOA encourages pilot and feasibility clinical and translational research studies of digestive and liver diseases. (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - November 15, 2017 Category: Endocrinology Source Type: funding
Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01- Clinical Trial Optional)
Funding Opportunity RFA-DK-17-038 from the NIH Guide for Grants and Contracts. The goal of this FOA is to support innovative, basic and translational research in two areas, gastrointestinal (GI) mucosal immunology and liver disease. The emphasis for GI mucosal immunology is on elucidation of mechanisms whereby innate and adaptive immunity in the GI tract interacts with HIV infection in the presence or absence of antiretroviral therapy (ART) and contributes to HIV infection, persistence, disruption of GI homeostasis, and pathogenesis. The emphasis for liver disease is on pathophysiologic mechanisms of injury to the liver...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 9, 2017 Category: Research Source Type: funding
Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01- Clinical Trial Optional)
The goal of this FOA is to support innovative, basic and translational research in two areas, gastrointestinal (GI) mucosal immunology and liver disease. The emphasis for GI mucosal immunology is on elucidation of mechanisms whereby innate and adaptive immunity in the GI tract interacts with HIV infection in the presence or absence of antiretroviral therapy (ART) and contributes to HIV infection, persistence, disruption of GI homeostasis, and pathogenesis. The emphasis for liver disease is on pathophysiologic mechanisms of injury to the liver and the biliary system during HIV infection and epidemiological studies of liver ...
Source: NIDDK Funding Opportunities - November 9, 2017 Category: Endocrinology Source Type: funding
Consortium on Translational Research in Early Detection of Liver Cancer (Clinical and Research Centers (U01)
Funding Opportunity RFA-CA-17-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The Consortium will consist of several Translational Research Centers (TRCs, to be supported by this U01 FOA) and a Data Management and Coordinating Center (DMCC, to be supported a companion U24 FOA, RFA-CA-17-028). The TRCs will conduct studies to improve the surveillance of liver cancer in members of high-risk populations, increase the fraction of...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 21, 2017 Category: Research Source Type: funding
